Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2
Status:
Recruiting
Trial end date:
2022-08-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well adavosertib works in treating patients with
SETD2-deficient solid tumors that have spread to other places in the body
(advanced/metastatic). Adavosertib may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth.